NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This open-label, randomized, and controlled clinical trial aims to determine the feasibility
and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to
modulate the gut microbiota and treat early-stage suspected or confirmed symptomatic COVID-19
patients.